S108 Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials. (12th November 2015)

• Record Type: Journal Article
• Authors: Kolb, M; Kimura, T; Stowasser, S; Hallmann, C; Richeldi, L
• Is Part Of: Thorax. Volume 70(2015)Supplement 3
• Page Start: A62
• Page End: A62
• Publication Date: 2015-11-12
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2015-207770.114
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: The two replicate, randomised, placebo-controlled, 52-week Phase III INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg twice daily (bid) in patients with idiopathic pulmonary fibrosis (IPF). Patients with forced vital capacity (FVC) ≥50% predicted were included. The primary endpoint, the annual rate of decline in FVC, was significantly reduced in the nintedanib group compared with placebo in both trials, consistent with a slowing of disease progression. Key secondary endpoints were time to first acute exacerbation and change from baseline in St. George's Respiratory Questionnaire total score, both over 52 weeks. In a pre-specified subgroup analysis of patients with baseline FVC ≤70% versus >70% predicted, the treatment effect of nintedanib on decline in FVC was consistent in both subgroups. Methods: A post-hoc subgroup analysis of patients with baseline FVC >90% versus ≤90% predicted was undertaken using pooled data from the INPULSIS® trials to investigate whether patients with marginally impaired FVC receive the same benefit from nintedanib. Results: 274 patients (nintedanib 166, placebo 108) had baseline FVC >90% predicted and 787 patients (nintedanib 472, placebo 315) had baseline FVC ≤90% predicted. There was no significant treatment-by-subgroup interaction for the primary endpoint (p = 0.5300); in patients with baseline FVC >90% predicted, the adjusted annual rate of decline in FVC was -91.5 mL/year with nintedanib and -224.6 mL/year with placebo (difference: 133.1 mL/year [95% CI: 68.0, 198.2]) while in patients with baseline FVC ≤90% predicted, it was -121.5 mL/year with nintedanib and -223.6 mL/year with placebo (difference: 102.1 mL/year [95% CI: 61.9, 142.3]). Consistent results were observed for changes from baseline in FVC over time (Figure 1 ). No significant treatment-by-subgroup interaction was observed for the key secondary endpoints. The frequency of adverse events and serious adverse events was comparable between the treatment arms of each subgroup. Conclusion: In a subgroup analysis of pooled data from the INPULSIS® trials, nintedanib 150 mg bid slowed the decline in lung function in patients with IPF independent of degree of lung function impairment at baseline, suggesting that patients with marginally impaired FVC also benefit from treatment with nintedanib.